Pleasanton, CA-based Sanarus Medical may soon bring to market an ultrasound-guided biopsy tool called Centrica. The product, described as a rotational core biopsy system, uses a new approach to breast tissue sampling that the company considers more
Pleasanton, CA-based Sanarus Medical may soon bring to market an ultrasound-guided biopsy tool called Centrica. The product, described as a rotational core biopsy system, uses a new approach to breast tissue sampling that the company considers more cost-effective and less invasive than open, surgical biopsy options. The procedure creates a 3 to 4-mm incision in the breast and requires no general anesthesia or stitches. Under ultrasound visualization, a small needle is placed directly into the tissue. Once placement is confirmed via ultrasound, the immobilized lesion is “stick frozen” for a few seconds, which secures the targeted tissue and enables a large tissue sample to be removed for evaluation. Centrica, which has been cleared by the FDA, is the first in a series of ultrasound-guided technologies being developed by Sanarus.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.